Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study.
Kelly-Morland C, Rudman S, Nathan P, Mallett S, Montana G, Cook G, Goh V. Kelly-Morland C, et al. Among authors: nathan p. BMC Cancer. 2017 Jun 2;17(1):392. doi: 10.1186/s12885-017-3371-9. BMC Cancer. 2017. PMID: 28578690 Free PMC article. Clinical Trial.
Sunitinib and other targeted therapies for renal cell carcinoma.
Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T. Powles T, et al. Among authors: nathan p. Br J Cancer. 2011 Mar 1;104(5):741-5. doi: 10.1038/sj.bjc.6606061. Epub 2011 Jan 25. Br J Cancer. 2011. PMID: 21266975 Free PMC article. Review.
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.
Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ. Lee CP, et al. Among authors: nathan pd. Oncologist. 2015 Apr;20(4):368-9. doi: 10.1634/theoncologist.2014-0250. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795637 Free PMC article. Clinical Trial.
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan PD, Larkin J, Gore M, Vasudev NS, Reynolds AR. Bridgeman VL, et al. Mol Cancer Ther. 2016 Jan;15(1):172-83. doi: 10.1158/1535-7163.MCT-15-0170. Epub 2015 Oct 20. Mol Cancer Ther. 2016. PMID: 26487278 Free article.
1,141 results